Shots:

• Dicerna to receive $200M up front and up to $1.47B development- regulatory and commercial milestones and royalties based on the sales of DCR-HBVS. Roche to get WW license to develop & commercialize DCR-HBVS utilizing Dicerna’s GalXC RNAi platform technology
• Dicerna holds an option to co-fund global development of DCR-HBVS- which if exercised- Dicerna will get enhanced royalties and rights to co-promote therapies including DCR-HBVS in the US
• Additionally- the companies are collaborating to develop additional therapies targeting multiple additional humans and viral genes associated with HBV infection utilizing the technologies of both the companies for which Dicerna will receive additional milestones and royalties on developed products

Click here to­ read full press release/ article 

Ref: Business wire | Image: Roche